Swiss National Bank Raises Holdings in Glaukos Co. (NYSE:GKOS)

Swiss National Bank lifted its holdings in Glaukos Co. (NYSE:GKOS - Free Report) by 9.9% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 108,100 shares of the medical instruments supplier's stock after purchasing an additional 9,700 shares during the quarter. Swiss National Bank owned 0.20% of Glaukos worth $16,209,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Mutual of America Capital Management LLC boosted its stake in Glaukos by 1.1% during the fourth quarter. Mutual of America Capital Management LLC now owns 8,353 shares of the medical instruments supplier's stock worth $1,252,000 after buying an additional 89 shares during the period. HighTower Advisors LLC boosted its stake in Glaukos by 2.8% during the fourth quarter. HighTower Advisors LLC now owns 3,298 shares of the medical instruments supplier's stock worth $495,000 after buying an additional 91 shares during the period. Louisiana State Employees Retirement System boosted its stake in Glaukos by 0.4% during the fourth quarter. Louisiana State Employees Retirement System now owns 26,700 shares of the medical instruments supplier's stock worth $4,003,000 after buying an additional 100 shares during the period. Handelsbanken Fonder AB boosted its stake in Glaukos by 0.7% during the fourth quarter. Handelsbanken Fonder AB now owns 14,700 shares of the medical instruments supplier's stock worth $2,204,000 after buying an additional 100 shares during the period. Finally, KBC Group NV boosted its stake in Glaukos by 16.2% during the third quarter. KBC Group NV now owns 1,445 shares of the medical instruments supplier's stock worth $188,000 after buying an additional 201 shares during the period. 99.04% of the stock is owned by hedge funds and other institutional investors.

Remove Ads

Insider Buying and Selling at Glaukos

In other Glaukos news, insider Tomas Navratil sold 3,416 shares of Glaukos stock in a transaction dated Friday, February 14th. The stock was sold at an average price of $147.14, for a total value of $502,630.24. Following the transaction, the insider now owns 72,437 shares in the company, valued at $10,658,380.18. The trade was a 4.50 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 6.40% of the stock is owned by insiders.

Glaukos Stock Up 1.4 %

Shares of GKOS stock traded up $1.39 on Friday, hitting $102.02. The stock had a trading volume of 1,040,792 shares, compared to its average volume of 586,642. The company has a quick ratio of 4.71, a current ratio of 5.54 and a debt-to-equity ratio of 0.19. The business has a 50 day moving average price of $135.32 and a 200 day moving average price of $136.53. The company has a market cap of $5.77 billion, a PE ratio of -35.55 and a beta of 0.99. Glaukos Co. has a one year low of $87.31 and a one year high of $163.71.

Glaukos (NYSE:GKOS - Get Free Report) last released its quarterly earnings data on Thursday, February 20th. The medical instruments supplier reported ($0.40) earnings per share for the quarter, missing the consensus estimate of ($0.38) by ($0.02). The firm had revenue of $105.50 million during the quarter, compared to the consensus estimate of $100.72 million. Glaukos had a negative net margin of 39.04% and a negative return on equity of 16.53%. Research analysts anticipate that Glaukos Co. will post -1.08 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research analysts have commented on the stock. Needham & Company LLC lifted their price objective on shares of Glaukos from $149.00 to $176.00 and gave the stock a "buy" rating in a research note on Friday, February 21st. Stephens upgraded Glaukos to a "strong-buy" rating in a research report on Monday, December 2nd. Mizuho upgraded Glaukos from a "neutral" rating to an "outperform" rating and lifted their target price for the stock from $140.00 to $200.00 in a research report on Wednesday, February 19th. Truist Financial lifted their target price on Glaukos from $152.00 to $185.00 and gave the stock a "buy" rating in a research report on Wednesday, December 18th. Finally, Citigroup upgraded Glaukos from a "neutral" rating to a "buy" rating and lifted their target price for the stock from $132.00 to $162.00 in a research report on Wednesday, December 11th. One research analyst has rated the stock with a sell rating, one has given a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $163.25.

Glaukos Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.